The introduction of inhibitors may reduce the effectiveness of treatment
The introduction of immune checkpoint inhibitors (nivolumab, ipilimumab, pembrolizumab and others) in the evening may reduce the effectiveness of treatment, compared with treatment in the morning and afternoon.
A study was conducted that included 299 patients with metastatic melanoma who received 4 or more doses of immunotherapy between 2012 and 2020. As a result, after more than two years of observation, it was found that the administration of these drugs in the evening hours is an independent adverse prognostic factor. The point of "watershed" was the time of 16:30. Of those treated in the evening, only 50% of patients survived 4.8 years or more. Among those treated in the morning, more than 50% of patients lived longer than the time of the study.
You can read more here.
We thank E.F. Satirova, head of the department of antitumor drug treatment, oncologist K+31 West, for the up-to-date information.
